Physician profile
Mark A Bigda
NPI 1043292089
$1,460.41
in general payments reported to CMS, 2019-2025
13 companies · $81.26 in 2025
The $81.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.12 · 2020: $12.40 · 2022: $88.83 · 2023: $575 · 2024: $622 · 2025: $81.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $231.32 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $223.32 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $193.95 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $158.28 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $140.32 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $133.77 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $101.17 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $94.74 | 2022-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $55.64 | 2024 | Veozah |
| Pharming Healthcare, INC. | $50.30 | 2023-2024 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $38.88 | 2023 | Trintellix |
| Antares Pharma, INC. | $20.15 | 2024 | Xyosted |
| Abbvie INC. | $18.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bigda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.